Stoneprime US develops AI algorithms that automate the work of scientific analysts by assessing the growth potential of over 500 US-listed biotech companies. The platform combines qualitative analysis of management teams, research quality, and scientific citations with quantitative analysis of stock micro-patterns to identify optimal entry points. Its technology is patent pending (No. 63/634,059).
Funding
Funding not disclosed
Founders
Product
Problem
Evaluating the growth potential of biotech companies requires intensive manual analysis of scientific research, management capabilities, and market dynamics, a process that is time-consuming, subjective, and prone to human error. Investors and analysts struggle to systematically process the vast volume of scientific publications, clinical data, and stock movement patterns needed to make informed decisions.
Solution
Stoneprime US provides an AI-driven platform that automates the role of scientific analysts by assessing the potential development of over 500 biotech companies in the US stock market. The system employs qualitative AI to examine management team resources and capabilities, research quality, competitor analysis, congress abstracts, published papers, and scientific citations. Simultaneously, quantitative AI identifies micro-patterns in stock movements to determine optimal entry points, analyzing each asset from multiple perspectives to uncover signals invisible to human observation. The combined approach delivers a comprehensive, data-driven evaluation of biotech firms' growth prospects.
Target Audience
Primary users are investors, financial analysts, and asset managers focused on the US biotech sector who need automated, data-driven assessments of company growth potential and optimal stock entry timing.
Features
- Qualitative AI algorithms that assess management team CVs, capabilities, and resources
- Automated analysis of scientific research quality, competitor positioning, congress abstracts, and published papers
- Quantitative AI that identifies micro-patterns in stock movements to pinpoint ideal entry points
- Multi-perspective asset profiling that detects market signals invisible to human analysis
- Coverage of over 500 companies in the biotech sector
- Patent-pending technology (No. 63/634,059)